COVID-19

NVX-CoV2373, a protein-based COVID-19 vaccine, may increase the country's vaccination rate for those hesitant to receive other vaccines.

Moderna is completing regulatory submissions for mRNA-1273.214 in preparation for the fall booster season, based on clinical data showing that the booster candidate has a significantly higher neutralizing antibody response against all tested variants including Omicron BA.4/5.

A booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1.

David Pope, PharmD, CDE, the EVP of Innovation and Industry Relations at OmniSYS, discusses the FDA’s announcement updating pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid.

Paxlovid treats COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

As we learn more about inflammatory syndromes, we may get better at using laboratory tests to identify and isolate the actual cellular and chemical processes that drive them.

Companies, FDA caught unaware by surge in virus cases, leading to shortage of critical items.

The study included the BNT162b2 and CoronaVac vaccines, which are the only COVID-19 vaccines authorized for emergency use in Hong Kong.

More than three-quarters of deaths averted were attributed to the direct protection against severe symptoms provided by vaccination, leading to lower mortality rates.

Infection in pregnancy increases the risk for preterm delivery and other adverse pregnancy outcomes, including stillbirth.

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

The Sanofi-GSK vaccine demonstrated a favorable safety and tolerability profile throughout stage 1 and stage 2 of the VAT08 trial, according to the researchers.

Pharmacy and public health have a long history of collaboration during an emergency.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses his research investigating the persistence of taste and smell loss among patients who have been infected and reinfected with COVID-19.

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.

Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against the variant.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses how patients who have experienced a loss of taste and smell following COVID-19 infection may be impacted by this symptom for years without realizing it.

Now we must turn our focus to all recommended vaccinations.

Hispanic and individuals with lower incomes experienced sharper drops, reflecting emerging barriers and exacerbation of long-standing hurdles, analysis results indicate.

Since the COVID-19 pandemic began, more than 10.6 million children have tested positive for the virus in the United States.

Paxlovid treats COVID-19 in adults who do not require supplemental oxygen and who are at an increased risk of progression to severe disease.

Although the COVID-19 pandemic saw the rapid hemorrhaging of women from careers in science and medicine, research shows the toxicity experienced by women may be structural in nature.

Data from the phase 2/3 TeenCOVE trial in adolescents met the primary immunogenicity endpoint.